Posted by Michael Wonder on 30 Oct 2022
CytoDyn announces voluntary withdrawal of BLA for HIV-MDR due to CRO data management issues
28 October 2022 - Company to complete and submit responses to FDA clinical hold.
CytoDyn today announced that it has voluntarily withdrawn its pending biologics license application for leronlimab as a combination therapy in persons living with HIV with resistance to highly active antiretroviral therapy in the HIV multi-drug resistant population.
